• Thu. Sep 29th, 2022

Blackhawk’s Mindbio Therapeutics Announces Research Collaborators at University of Auckland Receive Grant Funding of $1.44 Million for LSD Microdosing Trials in Major Depressive Disorder

ByThe Newswire

Jul 30, 2022
Blackhawk Growth Corp.


  • Successful grant comes after recent successful completion of Phase 1 LSD Microdosing LSD Trial in 80 participants 

  • MindBio working exclusively in psychedelic microdosing clinical trials with University of Auckland research collaborators to develop IP and novel microdosing treatments 

Vancouver, British Columbia – TheNewswire – July 25, 2022 – Blackhawk Growth Corp. BLR; (Frankfurt:0JJ); BLRZF (the “Company” or “Blackhawk“) subsidiary, MindBio Therapeutics’ (“MindBio”) research collaborators at the University of Auckland in New Zealand have received NZ$1.44 million in funding from the Health Research Council of New Zealand  to conduct a trial of LSD (Lysergic Acid Diethylamide) microdosing in patients with Major Depressive Disorder.

The grant funding comes after the recent successful completion of a Phase 1 Clinical Trial in 80 healthy participants.  The data from this Phase 1 trial is currently being collated and MindBio will make further announcements as information comes to hand.

MindBio is working exclusively in psychedelic microdosing clinical trials with scientific collaborators at the University of Auckland to develop intellectual property and novel microdosing treatments for mental health conditions that can be commercialized and used to treat patients in the primary health care system.

“We are proud of the work of our scientific collaborators and the substantial support shown is testament to the calibre of scientists leading the project.   We are determined to develop game-changing treatments for mental health conditions” said Frederick Pels, CEO of Blackhawk Growth Corp.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, Digital Mind Therapeutics, MindBio Therapeutics, Blum Distributors Ltd. as well as an equity position in Gaia Grow Corp.

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

About the University of Auckland

The University of Auckland is Aotearoa New Zealand’s leading university, ranked 87th in the world in the QS World Rankings 2022 and sixth in the Times Higher Education University Impact Rankings that measure performance against the Sustainable Development Goals. High-quality research across the full range of disciplines, represented by its eight faculties and two Large-Scale Research Institutes, ensures its place among the leading international research universities.

Copyright (c) 2022 TheNewswire – All rights reserved.



Image and article originally from www.benzinga.com. Read the original article here.